Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Authors :: Ernesto Wasserman
Petronella O. Witteveen
J.H.M. Schellens
M. Magin Ferrer
Valentina Boni
Andreea Varga
K. Bol
A. Amatu
Maria Alsina
Virtudes Moreno
A. Lourbakos
Source :: Annals of Oncology. 29:viii223-viii224
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Bispecific antibody
business.industry
Cancer
Hematology
Gastroesophageal Junction
medicine.disease
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Phase i ii
Oncology
030220 oncology & carcinogenesis
Phase (matter)
Cancer research
Medicine
Single agent
business

Full Text Access

Tools